GenScript at Tides Expert Opinion Webinar Series

What Will be Covered

With the 4^th approval on CAR-T therapy (Breyanzi) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment. The delivery of specifically designed chimeric antigen receptor (CAR) or T cell receptor (TCR) encoding component can be done by viral vectors, but this approach has limitations like random insertion and complicated vector manufacture process. Nowadays, with the power of CRISPR gene editing, precise and efficient T cell engineering can be carried out in a non-viral, plasmid-free manner.

GenScript has develop several tools to overcome these challenges. We will show data on how GenScript can efficiently manufacture sgRNA and DNA payloads for precise CAR/TCR KI in T cells. With this upgraded capability and recent advances in non-viral delivery of CRISPR components, it will become increasingly possible to efficiently and precisely engineer T cells with minimal off-target impact.